



#25I-18 ELISA kit for Human Rotavirus Detection

Rotavirus infection is the most frequent cause of severe infant diarrheic disease worldwide.

In Argentina, the Rotavirus vaccine has been incorporated in the mandatory vaccination schedule for disease prevention since 2015. This had a positive impact in reducing acute diarrheas caused by the main viral strains in circulation worldwide.

Epidemiological disease vigilance is important both in countries with and without mandatory vaccination, in order to minimize undiagnosed cases and reduce unnecessary antibiotics use. Presently, the emergence of new viral strains has been observed after the global implementation of vaccines registered in recent years.

At INCUINTA, we developed specific Rotavirus anti-VP6 nanobodies, to be used in the development of an ELISA immunoassay to detect Human Rotavirus.

ADVANTAGES:

- Nanobodies with greater affinity and specificity than conventional antibodies.
- Easy access technology for fast and simple detection in laboratories, hospitals and the private sector.
- Industrial scaling feasibility.
- Validated against national samples panels.
- Validated for South American bovine, equine, swine and camelid herds.

TECHNOLOGY READINESS LEVEL:

Analytic and diagnostic method validation tests in the actual environment. Inter-laboratory tests in the nodes of the Vigilance Network coordinated by the INEI Anlis Malbrán, performed throughout two consecutive years. Production of two lots. Presently under registration in SENASA and ANMAT.

INTELLECTUAL PROPERTY RIGHTS STATUS:

Formulation protected by invention patent 100% proprietary to INTA. PCT/EP08/59745

DNA de Vinculación Tecnológica y Relaciones Institucionales - National Coordination Office for Technological Cooperation and Institutional Relations, INTA . Intellectual Property Department-Technological Antenna

Dr. Mariana Nanni nanni.mariana@inta.gob.ar



Secretaría de Agroindustria
Ministerio de Producción y Trabajo
Presidencia de la Nación